Results 21 to 30 of about 932 (190)
Кардиоваскулярная терапия и профилактика, 2013 The paper focuses on cytoprotective and additional effects of mildronate. The emphasis is on the latest original research evidence on mildronate effects in the settings of cardiovascular and cerebral ischemia.
I. G. Gordeev, E. O. Taratukhin
doaj +1 more source
Metabolic cardioprotection: new concepts in implementation of cardioprotective effects of meldonium [PDF]
, 2016 Recent studies confirm the need to find means to correct ischemic / reperfusion injury due to the hemodynamic medicine, which are already known do not have the proper cardioprotective effects.
Danilenko, L. M. +3 more
core +2 more sources
Фармакологическая защита ишемизированного миокарда производными 3-(2,2,2-триметилгидразиния) пропионата и оценка их антиоксидантной активности [PDF]
, 2015 Приведены результаты исследования антиоксидантной (в условиях in vitro) и противоишемической эффективности в ряду производных 3-(2,2,2- триметилгидразиния) пропионата Милдронат® и его ...
Даниленко, Л. М. +2 more
core +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study the effect of treatment with metabolic corrector mildronate on lipid profile, inflammatory factors and endothelium function in patients with ischemic heart disease (IHD).Material and methods.
I. V. Sergienko +6 more
doaj +3 more sources
Metabolic (cytoprotective) therapy of menopausal disturbances
Кардиоваскулярная терапия и профилактика, 2011 The paper presents modern views on cardiovascular aspects of menopause and metabolic therapy of menopausal disturbances with meldonium (Mildronate®). The role of estrogen deficiency in climacteric disturbance development, key pathogenetic mechanisms of ...
S. N. Tolstov, V. B. Mychka
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2016 Aim. To study effect of mildronate on stream-dependent vasodilation in patients with chronic heart failure (CHF).Material and methods. 30 patients with CHF taking standard therapy (diuretic, ACE inhibitor, β- blocker) as well as 30 healthy volunteers ...
L. G. Voronkov +2 more
doaj +1 more source
Кардиоваскулярная терапия и профилактика, 2012 Aim. To compare the effects of Mildronate and hormone replacement therapy (HRT) with estradiol (1 mg) and drospirenone, DSPR (2 mg) on circadian blood pressure (BP) profile, arterial structure and function, and vascular stiffness parameters in women with
S. N. Tolstov +4 more
doaj +1 more source
The synthesis of N-(4-aryl-thiazol-2-yl)-N1-(4,5,6,7-tetrahydro-3H-azepin-2-yl)-hydrazine hydrobromides and the cardioprotective activity of (41-methoxyphenyl-thiazol-2-yl) derivative [PDF]
Pharmacia, 2021 A novel series of N-(4-aryl-thiazol-2-yl)-N1-(4,5,6,7-tetrahydro-3Н-azepin-2-yl)-hydrazine derivatives were synthesized by interaction of equimolar quantities of substituted α-bromacetophenones with thiosemicarbazide and characterized on the basis of ...
Sergii А. Demchenko +5 more
doaj +3 more sources
Mildronate in cardiology practice – current evidence, ongoing research, and future perspectives
Кардиоваскулярная терапия и профилактика, 2012 The review discusses the benefits and various practical aspects of the new cardioprotector mildronate use in cardiology. The latest evidence on the mildronate role in complex therapy of patients with stable angina, or patients in the rehabilitation ...
V. P. Mikhin +3 more
doaj +1 more source
Lipidomics Provides New Insight into Pathogenesis and Therapeutic Targets of the Ischemia-Reperfusion Injury [PDF]
, 2021 Lipids play an essential role in both tissue protection and damage. Tissue ischemia creates anaerobic conditions in which enzyme inactivation occurs, and reperfusion can initiate oxidative stress that leads to harmful changes in membrane lipids, the ...
Dordevic, J +9 more
core +2 more sources